Compare IVDA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | CVKD |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 10.3M |
| IPO Year | N/A | 2022 |
| Metric | IVDA | CVKD |
|---|---|---|
| Price | $0.34 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 14.4M | 73.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $2.55 |
| 52 Week High | $2.58 | $14.64 |
| Indicator | IVDA | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 46.91 |
| Support Level | $0.25 | $2.55 |
| Resistance Level | $0.42 | $5.99 |
| Average True Range (ATR) | 0.07 | 0.55 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 17.24 | 62.13 |
Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.